Edition:
United States

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

103.70CHF
7 Dec 2018
Change (% chg)

CHF0.80 (+0.78%)
Prev Close
CHF102.90
Open
CHF103.10
Day's High
CHF105.30
Day's Low
CHF103.10
Volume
16,405
Avg. Vol
17,876
52-wk High
CHF150.70
52-wk Low
CHF99.50

Chart for

About

COSMO Pharmaceuticals SA is a Luxembourg-based pharmaceutical company engaged in the development and production of drugs against selected gastrointestinal diseases. Its clinical research aims to treat Inflammatory Bowel Diseases (IBD), such as ulcerative colitis and Crohn’s disease, as well as colon infections and skin... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): €1,965.91
Shares Outstanding(Mil.): 15.04
Dividend: --
Yield (%): --

Financials

  COPN.S Industry Sector
P/E (TTM): -- 31.13 33.63
EPS (TTM): 0.24 -- --
ROI: 5.61 15.55 15.02
ROE: 6.12 16.92 16.60

BRIEF-Cosmo Pharmaceuticals Launches Offering Of Senior Unsecured Convertible Bonds Due 2023

* LAUNCH OF OFFERING OF SENIOR UNSECURED CONVERTIBLE BONDS DUE 2023

Nov 28 2018

BRIEF-Cosmo Pharmaceuticals: FDA Grants Approval For Aemcolo (Tm) (Rifamycin)

* FDA GRANTS APPROVAL FOR AEMCOLO (TM) (RIFAMYCIN), THE FIRST APPROVED ANTIBIOTIC TO TREAT TRAVELER'S DIARRHEA FOR TEN YEARS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 19 2018

BRIEF-Cassiopea Enters Into Loan Agreement With Cosmo Pharmaceuticals

* COSMO PHARMACEUTICALS HAS OFFERED AN UNSECURED CREDIT LINE OF EUR 10 MILLION THAT CAN BE INCREASED TO EUR 20 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 11 2018

BRIEF-Cosmo Pharmaceuticals Updates On Type A Meeting Outcome For MB MMX

* METHYLENE BLUE MMX REGULATORY UPDATE: TYPE A MEETING OUTCOME

Sep 13 2018

BRIEF-Cosmo Pharmaceuticals H1 Revenue Up 15.2 Pct To EUR 36.7 Million

* H1 REVENUE UP 15.2% TO EUR36.7M DRIVEN BY UP-FRONT LICENSE FEESÂ

Jul 26 2018

Earnings vs. Estimates

No consensus analysis data available.